|Day Low/High||10.36 / 10.95|
|52 Wk Low/High||4.82 / 14.62|
Get ahead of the naysayers, says Jim Cramer. FANG and other tech leaders have gone cold, but they're not dead yet.
Investors in Adaptimmune Therapeutics PLC saw new options begin trading this week, for the December 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
In recent trading, shares of Adaptimmune Therapeutics PLC have crossed above the average analyst 12-month target price of $13.40, changing hands for $13.74/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.
In recent trading, shares of Adaptimmune Therapeutics PLC have crossed above the average analyst 12-month target price of $10.20, changing hands for $10.94/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Data provides confirmation of broad applicability of SPEAR TCR T-cell platform in solid tumors
Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
Here's what you need to know now for Monday, Jan. 22.
Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.
Investors in Adaptimmune Therapeutics PLC saw new options begin trading this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADAP options chain for the new February 16th contracts and identified one put and one call contract of particular interest.
Successful Manufacturing of SPEAR T-cells for a Patient at its Navy Yard Site and Agreement with Cell and Gene Therapy Catapult to Increase Vector Manufacturing Capacity
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Flagship Facility is new Base for U.K. Research and Development Operations
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADAP, CTRP, DCO, GRPN, KMT, NYMT, PBF, SAM, SFUN, SPAR, TPX Downgrades: AEGN, BATRA, BATRK, CMT, FNSR, KEM, KOF, LL, LQ, MX, NFG, NLS Initiations: DFIN, DZSI Read on to get TheStreet Quant Ratings' detailed report:
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.